This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

PTI-202

Pain Therapeutics, Inc.

Drug Names(s): PTI-202

Description: PTI-202 is an abuse-resistant, long-acting opioid painkiller.

Deal Structure: In November 2005, Pain Therapeutics and King Pharmaceuticals announced a broad strategic alliance to develop and commercialize four proprietary lead drug candidates. Under the terms of the agreement, King will make an upfront payment of $150 million in cash to Pain Therapeutics. Pain Therapeutics could alsoreceive additional milestone payments of up to $150 million in cash based on the successful clinical and regulatory development of Remoxy and other abuse-resistant opioid products. King is responsible for all R&D expenses relatedto this alliance.

Pain Therapeutics and King will form a joint operating committee to oversee drug development and commercialization strategies for the alliance.Pain Therapeutics will retain sole control of drug development activities through Phase II. The companies will jointly manage Phase III and New Drug Application submissions in the U.S. King will have this responsibility outside the U.S. Upon regulatory approval, King will assume sole control...See full deal structure in Biomedtracker

Partners: Pfizer Inc. DURECT Corporation


PTI-202 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug